Exact Sciences Logo
US30063P1057

Exact Sciences

Ins Portfolio
80% Chancen, 20% Gelassenheit: Aktien und Anleihen in einem LifeStrategy-ETF.Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +74,24(+29,54%). Der Median liegt bei +76,70(+33,83%).

Kaufen
  16
Halten
  1
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie7 / 18
Levermann-Strategie-2 / 13
Powered byaktien.guide

News

  • Foto von AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates

    AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates

    ALEXANDRIA, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) is proud to announce a new project, made possible through a grant from Exact Sciences, that aims to improve colorectal cancer screening rates.Physician associates/physician assistants (PAs) are often one of the first healthcare providers a patient sees, and thus are uniquely positioned to discuss screenings early on with patients.AAPA Chief Medical Officer Jennifer M. Orozco-Kolb, DMSc, PA-C, DFAAPA, said PAs play an important role in educating and encouraging patients to complete colorectal cancer screenings.“The 5-year survival rate for a patient who is diagnosed with colorectal cancer in the early stages is upward of 91%,” Orozco-Kolb said. “When a patient is diagnosed at a later stage, that survival rate drops to almost 14%. Screening through either at home DNA stool testing or traditional colonoscopy procedures should be considered when having conversations with patients about what works best for them.”The project consists of three phases. The first phase, which is underway, will feature focus group meetings with four federally qualified health centers (FQHCs) in Wisconsin and Arizona that previously received Exact Sciences funding to complete projects that improved colorectal cancer screening rates. These FQHCs were selected because they often serve underserved or uninsured patients who are less likely to access and complete colorectal cancer screenings.These focus group meetings are expected to be completed by February 2025, when the second phase of the project will begin. This phase involves taking lessons learned and best practices gathered during the focus groups and creating an innovative toolkit that can be widely used by providers across the country to improve their own colorectal cancer screening rates.The third phase will consist of taking the newly developed toolkit and implementing changes at select clinics across the country to measure outcomes.In 2024, the American Cancer Society ranked colorectal cancer as the third deadliest form of cancer in men, and fourth deadliest cancer in women. It's estimated that more than 152,000 people nationwide will be diagnosed with colorectal cancer this year.### Media Contacts: AAPA: Josh Birch, 443.614.5896 About the   American Academy of Physician Associates (AAPA) AAPA is the national membership organization for all physician associates/physician assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn, Instagram, and Twitter.» Mehr auf globenewswire.com

  • Foto von Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

    Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

    Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning.» Mehr auf seekingalpha.com

  • Foto von Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)

    Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript)

    Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today.» Mehr auf seekingalpha.com

Unternehmenszahlen

Im letzten Quartal hatte Exact Sciences einen Umsatz von +636,34 Mio und ein Nettoeinkommen von 34,33 Mio
(EUR)Sep. 2024
YOY
Umsatz+636,34 Mio7,21%
Bruttoeinkommen+460,25 Mio5,97%
Nettoeinkommen34,33 Mio4.677,83%
EBITDA+23,60 Mio63,42%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+10,54 Mrd
Anzahl Aktien
185,08 Mio
52 Wochen-Hoch/Tief
+76,34 - +38,94
DividendenNein
Beta
1,27
KGV (PE Ratio)
51,28
KGWV (PEG Ratio)
+2,21
KBV (PB Ratio)
+3,42
KUV (PS Ratio)
+4,08

Unternehmensprofil

Exact Sciences Corporation bietet in den Vereinigten Staaten und international Krebsvorsorge- und Diagnosetestprodukte an. Das Unternehmen bietet Cologuard an, einen nicht-invasiven DNA-Screening-Test auf Stuhlbasis zum Nachweis von DNA- und Hämoglobin-Biomarkern, die mit Darmkrebs und Krebsvorstufen in Verbindung stehen. Es bietet außerdem Oncotype DX, einen Genexpressionstest für Brust-, Prostata- und Dickdarmkrebs; Oncotype Test, einen Gewebetest, der ein Tumorprofil liefert, um die Therapieauswahl für Patienten mit fortgeschrittenem, metastasierendem, refraktärem oder rezidivierendem Krebs zu unterstützen; Oncotype DX AR-V7 Nucleus Detect Test, einen flüssigkeitsbasierten Test für Prostatakrebs im fortgeschrittenen Stadium; Oncomap ExTra, der ein vollständiges biologisches Bild bestimmter refraktärer, seltener oder aggressiver Krebsarten liefert; und Covid-19 Testdienstleistungen. Die Pipeline-Produkte des Unternehmens konzentrieren sich auf die Verbesserung der Leistungsmerkmale des Cologuard-Tests und die Entwicklung von Blut- und anderen flüssigkeitsbasierten Tests. Das Unternehmen hat Lizenzvereinbarungen mit der MAYO Foundation for Medical Education and Research und mit Hologic, Inc. Die Exact Sciences Corporation wurde 1995 gegründet und hat ihren Hauptsitz in Madison, Wisconsin.

Name
Exact Sciences
CEO
Kevin T. Conroy J.D.
SitzMadison, wi
USA
Website
Industrie
Biotechnologie
Börsengang
01.02.2001
Mitarbeiter6.500

Ticker Symbole

BörseSymbol
NASDAQ
EXAS
Frankfurt
EXK.F
Düsseldorf
EXK.DU
SIX
EXK.SW
München
EXK.MU
🍪

Parqet nutzt Cookies.Erfahre Mehr